ArticleCurrent microbiology2026
Comprehensive Genomic Characterization of the Marine Isolate Exiguobacterium profundum SW22: Insights into Adaptive Mechanisms and Biosynthetic Potential.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological potential of the marine peptide cyclo(L-phenylalanyl-L-prolyl) against both multidrug-resistant, gram-negative Acinetobacter baumannii and gram-positive Staphylococcus aureus: structure - activity relationship, computational and experimental studies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A marine bacterium, Exiguobacterium profundum SW22, was isolated from sediment in the Bay of Bengal and characterised for its adaptive and biotechnological potential. The strain formed light orange, circular colonies with Gram-positive rod morphology and exhibited catalase, oxidase, and amylase activities, utilised diverse carbohydrates, and was sensitive to all tested antibiotics. De novo whole-genome assembly using Unicycler resulted in a 3 Mbp circular chromosome (48.2% G + C). Genome annotation with Bakta identified 3,060 protein-coding genes, 68 tRNAs, 27 rRNAs, tmRNA, and non-coding RNAs. Phylogenomic analysis, including 16 S rRNA gene similarity, average nucleotide identity (97.1%) and digital DNA - DNA hybridization (91%), confirmed SW22 as E. profundum. The maximum-likelihood phylogeny placed SW22 within the E. profundum clade, with 100% bootstrap support. Fatty acid analysis revealed the presence of branched-chain iso- and anteiso-C17:0 and C18:0 species, indicating membrane adaptation to stress. Genome annotation classified 1,643 proteins into 24 KEGG categories, with notable representation in genetic information processing and carbohydrate metabolism. CAZyme profiling identified 69 carbohydrate-active enzymes across 41 clusters, including amylase-related islands. The antiSMASH predicted 17 biosynthetic gene clusters (saccharide, terpene, RiPPs), consistent with antimicrobial potential. SignalP 6.0 identified Sec-, Tat-, and pilin-type peptides with cleavage sites at residues 15–30, strongly correlated with transporter families (MFS r = 0.92; ABC r = 0.91). The results confirmed the presence of 910 Exiguobacterium core genes, 552 E. profundum-specific, and 116 SW22 strain-specific genes. The combined environmental resilience, metabolic versatility, and biosynthetic repertoire underscore the potential of SW22 as a promising source of novel biotechnological and pharmaceutical applications.
Indexed as
Identifiers
41779227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.